Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...
GentiBio, a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs), announced today the ...
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...
Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha ...
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr.
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...
One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
On day one of IPWatchdog’s 2024 LIVE program, Joseph Allen of the Bayh-Dole Coalition became the fourth recipient of the ...
ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback